Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 4, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 850,000 Ordinary shares of 25 pence each.
- Purchase Price Range: Highest price paid was 1,189.5 pence per share; lowest price paid was 1,173 pence per share.
- Treasury Holdings (Settled): 484,969,284 shares, representing 8.55% of total issued share capital.
- Treasury Holdings (Including Unsettled): 487,289,284 shares, representing 9.40% of total voting rights.
- Shares in Issue (Excluding Treasury): 5,185,986,556 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 850,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.40% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document serves strictly as a notification of the share buyback and the resulting capital structure.
Investor Verification Points
- Verify the total number of shares held in Treasury (484,969,284 settled) against the company's latest annual report.
- Confirm the total issued share capital excluding Treasury shares (5,185,986,556) for disclosure threshold calculations under Financial Services Authority rules.
- Note that the 9.40% Treasury holding figure includes shares purchased but not yet settled.